According to the latest report by IMARC Group, titled " Hereditary Angioedema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2033," the global hereditary angioedema market size is witnessing steady growth. Hereditary angioedema (HAE) is a rare, autosomal dominant disorder that results in recurrent episodes of swelling that affect the face, hands, feet, and genitals. It is characterized by submucosal swelling, recurrent nonpitting, nonpruritic, and subcutaneous experiences without the appearance of urticarial lesions. It causes extreme pain, nausea, vomiting, diarrhea, fatigue, muscle ache, tingling, headache, belly pain, hoarseness, and mood changes due to blood protein deficiency. It is classified into three types, including Type I HAE, Type II HAE, and Type III HAE, depending on the formation of a dysfunctional protein. Its treatment depends on the type and severity of symptoms but may include the use of medications, such as C1 inhibitor replacement therapy, kallikrein inhibitor, and androgen therapy.
Global Hereditary Angioedema Market Trends:
The increasing incidences of hereditary angioedema (HAE) among the masses are driving the global market. This can be supported by the growing prevalence of genetic mutations leading to the disorder, elevating the demand for preventive medical care to mitigate future illness and treatment. Moreover, ongoing technological advancements in molecular biology and genetics have led to more accurate and efficient diagnostic techniques and improving patient outcomes is strengthening the overall market. Additionally, the development of novel therapies, such as gene therapies and RNA-based therapies, is acting as another growth-inducing factor. In line with this, numerous major companies are focusing on extensive research and development (R&D) activities to introduce effective drugs and novel therapies is providing a boost to the market. Furthermore, the rising initiatives and investments by the governments to improve the overall healthcare infrastructure that facilitates faster diagnosis and provide optimal treatment and care to patients are creating a positive market outlook. Apart from this, the escalating demand for personalized treatments as they aid in providing treatments to the specific needs of individual patients based on their genetic makeup and medical history is impacting the market favorably. Other factors, including rising demand for preventive care, increasing focus on patient-centric care and the increasing number of clinical trials, are also impacting the market.
- On the basis of the countries, the market has been classified into the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan.
- This research study also offers a thorough overview of late-stage pipeline candidates and currently marketed medications for hereditary angioedema.
- The study also offers a thorough overview of the treatment practices for hereditary angioedema, the share of specific therapies, and the performance of key market players.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800